IL2 and melanoma: In a small retrospective single-center study of 27 patients, intralesional IL-2 was associated with improved PFS and OS in the subgroup of patients with locoregional progression and no active distant metastases.20 Given this data and considering the fact that intralesional treatment of cutaneous and subcutaneous metastases normally would not influence patients’ survival, we decided to focus our retrospective analysis only on melanoma stage III patients.